{"id":"W2746874591","doi":"10.1161/circulationaha.117.028136","title":"Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","year":2017,"lang":"en","type":"review","venue":"Circulation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"Banting and Best Diabetes Centre, University of Toronto; Medicines Company; Novo Nordisk; Intarcia Therapeutics; Sanofi; GlaxoSmithKline; Servier; Pfizer; Canada Research Chairs; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Semaglutide; Lixisenatide; Alogliptin; Saxagliptin; Liraglutide; Glucagon-like peptide 1 receptor; Internal medicine; Diabetes mellitus; Exenatide; Sitagliptin; Dipeptidyl peptidase-4; Type 2 diabetes; Myocardial infarction; Pharmacology; Endocrinology; Agonist; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000463309,0.000503971,0.00218511,0.000225656,0.0002961117,0.000159348,0.00008577881,0.0003390823,0.00001596337],"category_scores_gemma":[0.0000977942,0.0003603869,0.0008930886,0.0001084714,0.0002318097,0.0002082794,0.0001020802,0.0003173537,0.00006065125],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001624196,"about_ca_system_score_gemma":0.0001338926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002965078,"about_ca_topic_score_gemma":0.00001180837,"domain_scores_codex":[0.9978361,0.0001240899,0.000611752,0.0007695201,0.0003753769,0.0002831896],"domain_scores_gemma":[0.9981381,0.0001350405,0.0004279884,0.0009691733,0.000082415,0.0002472506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000009889033,0.0001196529,0.04266331,0.004318839,0.005079171,0.00002553363,0.00002570669,6.32325e-7,1.23487e-7,0.00004129094,0.0006196842,0.9470962],"study_design_scores_gemma":[0.001256874,0.0001276949,0.06297916,0.005296916,0.0120303,0.00002788529,0.00001992999,0.000005745072,1.269445e-7,0.000006253723,0.9179016,0.0003474838],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004737767,0.9896239,0.00005199469,0.00007660378,0.0005738623,0.002418913,0.00002258286,0.0001162228,0.002378131],"genre_scores_gemma":[0.00468827,0.9921079,0.0003687049,0.0000469869,0.0003998909,0.0001738255,0.0005966637,0.0000864912,0.00153124],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9467487,"threshold_uncertainty_score":0.9998848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1037989692238348,"score_gpt":0.3727103154527517,"score_spread":0.2689113462289168,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}